E. R. Squibb Sons, Inc.

Bristol-myers Squibb Compnay

Other

Squibb & Sons, Inc.

Kronenthal, David R.

David R Kronenthal

John K Thottathil

Jollie D Godfrey, Jr

Mark D Schwinden

Nachimuthu Soundararajan

Zhongping Shi

Ramesh N Patel

Richard H Mueller

Wen-Sen Li

Rajendra P Deshpande

Gerald L Powers

Sharon D Real

Yadagiri Pendri

Jagabandhu Das

William A Slusarchyk

Laszlo J Szarka

William H Koster

Yuping Qiu

John J Venit

Chiajen Lai

Qi Gao

Paul Alan Jass

James H Simpson

Shawn K Pack

Xinhua Qian

John L Dillon, Jr

Sushil K Srivastava

Keith Ramig

Pierre Sirard

Ramakrishnan Chidambaram

Kenneth J Natalie, Jr

Shan-Ming Kuang

Saibaba Racha

Jean Lajeunesse

Michael G Fakes

Atul S Kotnis

Wenhao Hu

Feng Qian

Paula L Kuester

Robert Droghini

Nathan Reising

Erqing Tang

Blisse J Vakkalagadda

Jeffrey A Robl

Robert Zahler

Christopher M Cimarusti

Gregory S Bisacchi

James Clifford Sutton

Spencer David Kimball

Bang-Chi Chen

David J Kucera

Richard P Polniaszek

Boguslaw Mudryk

Purushotham Vemishetti

Milan N Stojanovic

Chung-Pin H Chen

Amit Banerjee

Yadagiri R Pendri

Jeffrey M Evans

Shaopeng Wang

Prashant P Deshpande

Ambarish K Singh

Michael E Randazzo

Jeffrey T Bien

Jing Liang

Zhiwei Guo

Maotang X Zhou

Adrian Ortiz

Sunil S Patel

Siva Josyula Prasad

Theodor W Denzel

Rao S Bhandaru

Tamas Benkovics

Zhongmin Xu

Steven M Seiler

Roberto Droghini

Chris Sfouggatakis

Dhileepkumar Krishnamurty

Yeung Yu Chan

Sushil K Rijhwani

Uwe Treuner

John Kloss

Robert Waltermire

Charles Lewis

Yeung Y Chan

Milan Stojanovic

Jollie D Godfrey

Jr Kenneth J Natalie

A process for making the compound of Formula I utilizes the starting compound, together with sulfilimine and sulfoxide process steps later on. 

Sulfilimine and sulphoxide methods for producing festinavir

A process is provided for preparing triazole substituted azaindoleoxoacetic piperazine derivative. Novel intermediates produced in the above process, and novel N-1 and amorphous forms of a 1,2,3-triazole substituted azaindoloxoacetic piperazine derivatives and processes for producing such novel forms are also provided.

Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein

Methods for the synthesis of benzodiazepine compounds having farnesyl protein transferase inhibitory activity.

Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds

Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.

Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one

Mercaptoalkanoylamino lactam acids are recrystallized by treatment with an agent that minimizes the formation of disulfides. Suitable agents are bismercaptans, phosphine or phosphite reducing agents, zinc metal powder, and sodium hydrosulfite.

Recrystallization processes

Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions by including an agent which minimizes the amount of disulfides. Suitable agents are bismercaptans, phosphine or phosphate reducing agents, zinc metal powder, and sodium hydrosulfite.

Deprotection processes

The present invention relates to a process for the preparation of &agr;&prime; chloroketones, such as 4-phenyl-3-t-butyloxy-carbonylamino)-2-keto-1-chlorobutane by reacting certain aryl amino acid esters, e.g. N-(2-t-butoxycarbonyl)-L-phenylalanine-4-nitrophenyl ester, with a sulfur ylide compound to form the corresponding keto ylide compound which is then treated with a source of chloride and an organic acid.

Process for the preparation of &agr;' chloroketones

Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions by including an agent which minimizes the amount of disulfides. Suitable agents are bismercaptans, phosphine or phosphite reducing agents, zinc metal powder, and sodium hydrosulfite. Such agents are also employed in the recrystallization and reprocessing of the mercaptoalkanoylamino lactam acids.

Deprotection and recrystallization processes

Beta lactam compounds and their use as inhibitors of tryptase

Preparation of (S)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes

Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes

The glycinamide of the formula (I) ##STR1## is reacted with the dioxolane of the formula (II) ##STR2## wherein L is a leaving group such as iodo, bromo, alkylsulfonyloxy, or arylsulfonyloxy to give the dioxolane of the formula (III) ##STR3## Treatment of (III) gives the dioxolane pentanoic acid IV ##STR4## which can be converted to (S)-2-amino-6,6-dimethoxyhexanoic acid, methyl ester.

Preparation of (S)-2-amino-6, 6-dimethoxyhexanoic acid methyl ester via

A method of preparing compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof which comprises converting a compound of the formula ##STR2## where the R.sup.2 substituent contains a hydrogen atom which is more acidic than the starred (*) hydrogen atom in formula II, to the corresponding dianion of formula ##STR3## where M is a counterion preferably lithium or magnesium, using two equivalents of a base in an inert solvent such as tetrahydrofuran; then reacting compounds of formula IIA with an epoxide of formula ##STR4## to produce the compounds of formula I.

Process for preparing 4-arylamino-benzopyran and related compounds

Homocysteine analogs of the formula ##STR1## wherein P.sub.1 is a nitrogen protecting group and R.sub.6 is alkyl, substituted alkyl or benzyl are prepared by esterifying N-protected L-methionine, oxidizing, treating the resulting sulfoxide with an acid anhydride, treating the resulting product with an alkali metal hydroxide followed by removal of formaldehyde and the treatment with an acid anhydride or acid halide. The L-homocysteine analogs are useful as intermediates in the preparation of compounds containing a fused bicyclic ring.

Process for preparing homocystein analogs useful as intermediates for

Growing community of inventors

Yardley, PA, United States of America

David R Kronenthal